Reply: Randomized Controlled Trial of Resection Versus Radiotherapy After Induction Chemotherapy in Stage IIIA-N2 Non-Small Cell Lung Cancer  by Van Meerbeeck, Jan P. et al.
5. Hansen LA, Alexander N, Hogan ME, et al
Genetically null mice reveal a central role for
epidermal growth factor receptor in the differ-
entiation of the hair follicle and normal hair
development. Am J Pathol 1997;150:1959–
1975.
Reply: Randomized
Controlled Trial of
Resection Versus
Radiotherapy After
Induction
Chemotherapy in
Stage IIIA-N2
Non-Small Cell Lung
Cancer
To the Editor:
We recognize the excellent work
done by the authors of this editorial in
advancing the boundaries of lung cancer
surgery.1 However, the remarkable sur-
vival figures they cited were not all
based on an intention-to-treat analysis.
We also fear that their enthusiasm may
blur a rational interpretation of the re-
sults of EORTC 08941 for most clini-
cians who practice outside very special-
ized tertiary centers.2
One of the strengths of EORTC
08941 lies in the fact that study pa-
tients represent a fair case mix of pa-
tients with clinical stage IIIA-N2 non-
small cell lung cancer (NSCLC) who
were diagnosed, staged, and treated
between 1994 and 2002 in different
hospitals throughout Europe. As such,
these patients are more representative
of the real world than the series cited
by the editorial’s authors. The conclu-
sions of EORTC 08941 are applicable
to these real-world patients and insti-
tutions. Extrapolating the results of
highly selected series to the commu-
nity introduces a level of evidence that
is inappropriate for a highly prevalent
disease such as lung cancer.
The editorialists’ arguments that
surgery should be offered to patients
who are likely to be down-staged, and in
whom a complete resection can be ob-
tained with a lobectomy, are of a circu-
lar kind. However, inasmuch as these
factors are derived from a multivariable
analysis, then used to categorize the
same data, this is unsurprising. To prove
the predictive validity of these factors,
they should be applied to a new series,
not to the one from which they were
derived. More importantly, even if they
have been validated as predictive factors
associated with survival after surgery,
such analysis cannot be used to select
those likely to benefit most from surgery
because the notion of differential benefit
is based entirely on the presumption of
efficacy. Another flaw in using these
factors to select patients who are most
likely to benefit from radical surgery is
that they were all defined postopera-
tively. Completeness of resection can
only be defined post hoc, lymph node
status is revised as part of pathological
staging, and most—if not all—surgeons
are not likely to be certain before the
operation that a pneumonectomy will def-
initely not be necessary for an individual
patient with IIIA-N2, even in one showing
radiological evidence of response. This
fact is illustrated by the high rates of
pneumonectomy (28–44%) in the series
the editorialists quoted, a figure not dis-
similar to the rate of 46% observed in
EORTC 08941. If we are to have a set of
criteria by which to select or counsel pa-
tients, these criteria must be available be-
fore surgery and be validated before they
can be used.
We concur with the editorialists
that further research is needed to im-
prove the accuracy of diagnosing medi-
astinal down-staging by non-surgical
techniques such as endoscopic ultra-
sound and positron emission tomogra-
phy scan. However, the performance of
these techniques should be carefully as-
sessed in randomized trials, as their
costs are high and the characteristics of
the equipment might differ.
Several uncontrolled series with
chemoradiation regimens in stage III
NSCLC have been published, some
showing equally remarkable 5-year pa-
tient survival of 22% to 29%3,4 and be-
coming the standard of care in coopera-
tive groups without even being properly
controlled.5 These promising results
were subsequently not confirmed in ran-
domized phase III trials.6,7 The last de-
cade has seen the advent of several
novel radiation techniques that are likely
to improve the local control by the ad-
ministration of higher radiation doses to
smaller volumes, allowing for lesser
toxicity. There is a strong conviction
that modern radiotherapy as part of a mul-
timodality approach of patients with stage
III disease will further improve outcome
compared with the last decade. Opinions
differ as to whether these advances, result-
ing in less irradiation of healthy tissue,
should be confirmed by randomized trials
or whether matched case-control studies
will provide sufficient evidence.
The final answer can only be
obtained by randomizing an adequate
number of patients whose disease is
down-staged to either modern radio-
therapy or excellent thoracic surgery.
Because of the sample size needed and
the continuing improvements in radio-
therapy delivery, it is unlikely that a
trial of this size will ever be com-
pleted. Pending the results of these
deliberations, the message to the com-
munity should be that even after a
major response to induction therapy,
patients with stage IIIA-N2 NSCLC
should be primarily offered high-quality
modern radiation and that surgery should
be reserved for expert institutions and
preferably as a part of a clinical trial.8 All
the rest is speculation.
Jan P. Van Meerbeeck, MD, PhD
Paul E. Y. Van Schil, MD, PhD
Suresh Senan, MD, PhD
on behalf of the EORTC-Lung
Cancer Group
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